RootsAnalysishas done a detailed study on Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based onDegronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs,Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs,SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030, covering key aspects of theindustry’s evolution and identifying potential future growth opportunities.
Toorder this 330+ page report, which features 130+ figures and 145+ tables,please visit this - https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html
Key Market Insights
§ More than 85 small molecule protein degraders are currentlybeing evaluated for the treatment of various disease indications; in addition,there are 25+ technology platforms available for use in therapy developmentefforts
§ The pipeline features a variety of candidate drugs thattarget a wide range of disease-causing / associated proteins; majority of theexisting drug candidates are designed for administration via non-invasiveroutes
§ Although start-ups and mid-sized firms are spearheading theinnovation, several big pharmaceutical companies are also engaged in thisdomain
§ Close to 5,500 patients were estimated to have beenenrolled in clinical trials worldwide, evaluating a number of relevantpre-marketing end points across various phases of development
§ A number of prominent scientistsfrom renowned universities have emerged as key opinion leaders, owing to theiractive involvement in clinical development efforts
§ Published scientific literature indicates that bothindustry and academic players have made equal contributions to the innovationin this field; the major focus of such studies is presently on PROTACs
§ Foreseeing a lucrative future, several private and publicinvestors have invested over USD 3.5 billion across close to 100 instances offunding since 2014
§ The increasing interest in thisfield is also reflected in recent partnership activity; most of these deals arefocused on novel technology platforms, involving the active participation ofboth international and indigenous companies
§ Short term opportunity in this market is likely to bedriven by licensing activity, depending on the capability of novel technologiesto meet protein degrader design and development needs
§ As multiple mid-late stage drug candidates are approved formarketing, the long term opportunity is likely to be distributed acrossdifferent types of protein degraders, target therapeutic areas and variousglobal regions
Formore information please visit:
https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
